Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04373265
Other study ID # CORT125134-551
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 30, 2020
Est. completion date January 12, 2024

Study information

Verified date February 2024
Source Corcept Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will investigate the safety and efficacy of Relacorilant in combination with Pembrolizumab for Patients with Adrenocortical Carcinoma which Produces Too Much Stress Hormone (Cortisol).


Description:

Relacorilant is a small molecule antagonist of the glucocorticoid receptor (GR). The goal of this study is to assess the safety and efficacy of relacorilant when given in combination with pembrolizumab in patients with advanced adrenocortical carcinoma (ACC) which produces too much stress hormone (cortisol). Too much stress hormone (cortisol) is also called glucocorticoid (GC) excess. Eligible patients are those with advanced ACC that produces too much cortisol. Patients will receive treatment until progressive disease (PD) (per RECIST v1.1) is confirmed, experience unmanageable toxicity, or until other treatment discontinuation criteria are met. All patients will be followed for documentation of disease progression, survival information (i.e., date and cause of death) and subsequent treatment.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date January 12, 2024
Est. primary completion date October 17, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically or cytologically confirmed ACC (advanced unresectable and/or metastatic) - Measurable disease based upon RECIST v1.1 as determined by the Investigator. - Documented GC excess (too much cortisol). - For patients who have received mitotane within 3 months prior to screening, mitotane levels must be <4 mg/L at screening. - Eastern Cooperative Oncology Group (ECOG) performance status =2. - Adequate organ and bone marrow function (determined through blood and urine tests) - Negative pregnancy test for patients of childbearing potential at the Screening and every 6 weeks (+ or - 7 days) in female patients of childbearing potential. Exclusion Criteria: - Major surgery within 4 weeks prior to enrollment. If the participant underwent major surgery, they must have recovered adequately prior to starting study treatment. - Have received and responded (complete response [CR] or partial response [PR]) to prior treatment with any prior checkpoint inhibitor or any other agents targeting T-cell stimulation pathways - Taking a concomitant medication that is a strong Cytochrome P450 3A (CYP3A) inducer, or that is a substrate of CYP3A with a narrow therapeutic index - Known untreated parenchymal brain metastasis or have uncontrolled central nervous system (CNS) metastases. Patients must not require steroids and must be neurologically stable without corticosteroids for a minimum of 3 weeks prior to the commencement of the study. Patients with neurologic symptoms must undergo a CT/MRI to rule out occult CNS metastases. - Requirement for chronic systemic GC treatment, such as active autoimmune disease requiring systemic treatment (corticosteroids or other immunosuppressive medication) - Patients requiring inhaled glucocorticoids but have no other alternative treatment option if their condition deteriorates during the study. - Clinically relevant toxicity from prior systemic cytotoxic therapies or radiotherapy that in the opinion of the Investigator has not resolved to NCI-CTCAE v5.0 Grade 1 or less prior to the first dose of relacorilant. - Treated with the following prior to the first dose of relacorilant: 1. Any investigational product, systemic anticancer therapy, or radiation therapy within 21 days 2. Antibodies or anticancer vaccines within 60 days 3. Mifepristone or other GR antagonists within 5 half-lives of these medications 4. Adrenostatic medications within 5 half-lives of these medications - History of severe hypersensitivity to another monoclonal antibody - Other concurrent cancer or a history of another invasive malignancy within the last 3 years that has a likelihood of recurrence of >30% within the next 5 years. Adequately treated basal and squamous skin cancers, ductal carcinoma in situ, cervical cancer, prostate cancer, non-muscle invasive urothelial cancer or other tumors curatively treated with no evidence of disease are permissible. - Human immunodeficiency virus (HIV) or current chronic/active infection with hepatitis C virus or hepatitis B virus including: Chronic or active hepatitis B as diagnosed by serologic tests. In equivocal cases, hepatitis B or C polymerase chain reaction may be performed and must be negative for enrollment. - Clinically significant uncontrolled condition(s) or a condition which, in the opinion of the Investigator, may confound the results of the trial or interfere with the patient's participation, including but not limited to: 1. Unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction 3 months before study entry. 2. Active infection that requires parenteral antibiotics. 3. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Relacorilant
Relacorilant, 100 mg soft gel capsules orally once daily
Pembrolizumab
Pembrolizumab 400 mg infusion every 6 weeks

Locations

Country Name City State
United States Site #074, University of Michigan Medical School Ann Arbor Michigan
United States Site #183, The University of Texas M.D. Anderson Cancer Center Houston Texas
United States Site #051, Memorial Hospital New York New York
United States Site #030 Mayo Clinic Rochester Minnesota
United States Site #150, Stanford Cancer Center Stanford California
United States Site #007, Moffitt Cancer Center Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Corcept Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting Toxicity (DLT) Evaluate the percentage of patients with a dose-limiting toxicity Up to 12 weeks
Secondary Non-Progression Rate (NPR) Evaluate the non-progression rate (NPR) per RECIST v1.1 24 weeks from enrollment
Secondary Progression-Free Survival (PFS) Evaluate progression-free survival (PFS) per RECIST v1.1 From date of first treatment, until the date of first documented progression or date of death from any cause, whichever came first, up to month 24
Secondary Number of Participants with Adverse Events Adverse events (AEs) by severity grade using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0) Up to 37 days post-treatment
Secondary Plasma Concentrations of Relacorilant in Combination with Pembrolizumab in Patients with Advanced ACC and Glucocorticoid Excess Plasma concentrations of relacorilant in combination with pembrolizumab will be calculated in patients with advanced ACC and glucocorticoid excess Up to 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT06050057 - Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
Recruiting NCT06066333 - Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma Phase 2
Recruiting NCT03127774 - Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Phase 2
Completed NCT01048892 - Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Phase 1
Recruiting NCT00457587 - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
Recruiting NCT00669266 - Adrenal Tumors - Pathogenesis and Therapy
Recruiting NCT05999292 - Phase 1 Study of 68Ga-R8760 Phase 1
Completed NCT05361083 - First-in-human Evaluation of [18F]CETO Early Phase 1
Recruiting NCT05660889 - Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma
Completed NCT00003038 - Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Phase 1
Enrolling by invitation NCT03474237 - A Prospective Cohort Study for Patients With Adrenal Diseases
Recruiting NCT04119024 - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Phase 1
Enrolling by invitation NCT05036434 - Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma Phase 2
Terminated NCT05012397 - Milademetan in Advanced/Metastatic Solid Tumors Phase 2
Not yet recruiting NCT06333314 - Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI Phase 2
Withdrawn NCT00469469 - Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Phase 2
Completed NCT00002608 - Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Phase 2
Not yet recruiting NCT05839886 - The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma
Recruiting NCT05634577 - A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma Phase 2
Completed NCT00454103 - Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Phase 1/Phase 2